Fluorescent Light Bronchoscopy Plus White Light Bronchoscopy for Early Detection of Lung Cancer

N/ACompletedNCT00019201

National Cancer Institute (NCI)

Overview

RATIONALE: Fluorescent bronchoscopy, when used in combination with conventional white light bronchoscopy, may improve the ability to detect early lung cancer. PURPOSE: A pilot study to evaluate fluorescent light bronchoscopy plus conventional bronchoscopy as a tool for screening and detecting lung cancer in persons with completely resected head and neck cancer or successfully treated early-stage lung cancer.

OBJECTIVES: * Evaluate the efficacy of autofluorescence bronchoscopy using the Lung Imaging Fluorescence Endoscopic System with conventional white-light bronchoscopy for the early detection of lung cancer in selected patients with known or suspected bronchogenic carcinoma, completely resected head and neck cancer, and successfully treated early-stage lung cancer. * Determine the number of areas of moderate dysplasia, severe dysplasia, and carcinoma in situ in patients treated with surgery for lung cancer compared with patients treated with combined modality therapy. * Determine the ability of immunohistochemistry to predict whether lesions of moderate to severe dysplasia will progress to cancer. OUTLINE: If possible, patients produce a 3-day pooled sputum sample prior to bronchoscopy. Patients then undergo tracheobronchial white-light bronchoscopy followed by autofluorescence bronchoscopy using the Lung Imaging Fluorescence Endoscopic (LIFE) Device attached to a computerized video camera. Visualized tissue is classified as either normal, abnormal, or suspicious. Abnormal or suspicious tissue is biopsied, as is tissue from 1 or 2 randomly chosen normal sites. Immunohistochemical analysis of the biopsy material is conducted without knowledge of the bronchoscopic results. Patients unable to produce a sputum sample prior to bronchoscopy are required to do so after bronchoscopy. PROJECTED ACCRUAL: A total of 70 patients will be entered.

Study Type

INTERVENTIONAL

Purpose

SCREENING

Conditions

Head and Neck Cancer Lung Cancer

Interventions

cytology specimen collection procedureOTHER

immunohistochemistry staining methodOTHER

sputum cytologyOTHER

bronchoscopic and lung imaging studies

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

DISEASE CHARACTERISTICS: * The following diagnoses are eligible: * Known or suspected bronchogenic carcinoma scheduled for bronchoscopy as part of standard diagnostic or staging work-up * Completely resected stage I/II non-small cell lung cancer with no evidence of metastasis * Stage III non-small cell lung cancer with no evidence of disease for at least 2 years following treatment * Small cell lung cancer with no evidence of disease for at least 2 years following treatment * Completely resected head and neck cancer with no evidence of metastasis * Ability to produce sputum samples required PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * ECOG 0-2 Hematopoietic: * WBC 2,000-20,000 * Platelets at least 50,000 Hepatic: * Not specified Renal: * Not specified Cardiovascular: * No uncontrolled hypertension (i.e., systolic pressure greater than 200 mm Hg or diastolic pressure greater than 120 mm Hg) * No unstable angina Other: * No bleeding disorder * No allergic reaction to topical lidocaine * No pregnant women PRIOR CONCURRENT THERAPY: Biologic therapy * Not specified Chemotherapy * Not specified Endocrine therapy * Not specified Radiotherapy * At least 18 months since ionizing radiotherapy to the chest Surgery * See Disease Characteristics Other * At least 1 month since yttrium-aluminum-garnet (YAG) laser therapy to the lung * At least 3 months since fluorescent photosensitizing drugs (e.g., Photofrin)

Locations (1)

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support

Bethesda, Maryland, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.